FOAMIX PHARMACEUTICALS LTD's ticker is FOMX and the CUSIP is M46135105. A total of 65 filers reported holding FOAMIX PHARMACEUTICALS LTD in Q1 2019. The put-call ratio across all filers is 0.23 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $0 | -100.0% | 39 | -96.5% | 0.00% | – |
Q3 2019 | $3,000 | -25.0% | 1,127 | +0.3% | 0.00% | – |
Q1 2019 | $4,000 | +33.3% | 1,124 | +56.8% | 0.00% | – |
Q4 2018 | $3,000 | -93.0% | 717 | -90.4% | 0.00% | – |
Q3 2018 | $43,000 | -58.7% | 7,466 | -63.8% | 0.00% | – |
Q2 2018 | $104,000 | -92.4% | 20,646 | -92.3% | 0.00% | -100.0% |
Q1 2018 | $1,372,000 | +3330.0% | 267,396 | +3954.5% | 0.00% | – |
Q4 2017 | $40,000 | +3900.0% | 6,595 | +4326.2% | 0.00% | – |
Q2 2017 | $1,000 | 0.0% | 149 | 0.0% | 0.00% | – |
Q1 2017 | $1,000 | -92.9% | 149 | -88.1% | 0.00% | – |
Q4 2016 | $14,000 | -99.4% | 1,256 | -99.5% | 0.00% | -100.0% |
Q3 2016 | $2,431,000 | +14200.0% | 262,536 | +9293.1% | 0.00% | – |
Q2 2016 | $17,000 | -19.0% | 2,795 | -19.2% | 0.00% | – |
Q1 2016 | $21,000 | +425.0% | 3,458 | +543.9% | 0.00% | – |
Q4 2015 | $4,000 | +300.0% | 537 | +355.1% | 0.00% | – |
Q3 2015 | $1,000 | -98.4% | 118 | -98.1% | 0.00% | – |
Q2 2015 | $61,000 | +110.3% | 6,133 | +7.6% | 0.00% | – |
Q3 2014 | $29,000 | – | 5,700 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 4,781,708 | $28,738,000 | 4.90% |
DSC Advisors, L.P. | 1,187,604 | $7,138,000 | 4.14% |
Opaleye Management Inc. | 960,000 | $5,769,000 | 1.85% |
DAFNA Capital Management LLC | 352,741 | $2,120,000 | 1.14% |
Vivo Capital, LLC | 855,000 | $5,139,000 | 1.10% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 382,838 | $2,301,000 | 0.81% |
SENZAR ASSET MANAGEMENT, LLC | 377,397 | $2,268,000 | 0.58% |
Sio Capital Management, LLC | 131,200 | $789,000 | 0.44% |
Perceptive Advisors | 1,117,324 | $6,715,000 | 0.22% |
Tekla Capital Management LLC | 930,398 | $5,592,000 | 0.22% |